Plaquex®

History

Mid 1995 the wife of Dr. Sam Baxas developed chest pains and underwent a balloon angioplasty. Six weeks later her chest pain came back. She underwent another balloon angioplasty and six weeks later, the chest pains returned. Looking for an alternative treatment Dr. Sam stumbled on an  old remedy from Germany. His wife Heidi was the first patient to receive what is now known as Plaquex therapy and her chest pains vanished. With regular maintenance therapy they never came back. Dr. Sam began treating other patients and was surprised how much better this treatment worked than chelation therapy. He told colleagues about this amazing discovery and began supplying them. Today, 25 years later there are hundreds of doctors in the US and around the world who use Plaquex and tens of thousands of patients have been treated. Today his daughters carry on the task to spread the knowledge of Plaquex to doctors and patients.

The Plaquex® Formula has been in use for the past 70 years in about one-fourth of the world's countries1. It was originally developed to dissolve fatty embolus during and after trauma surgery. It is also used to treat liver and kidney disease2.

In the 1990's the use shifted to treating plaque deposits. The treatment was mostly done in combination with EDTA chelation infusions. Since then results have been so dramatic, that it has become a treatment in its own right.

  

Not only is the Plaquex® Formula used to remove fatty and hardened plaque from blood vessels, it is also applied for general anti aging purposes1. By observing their patients, many doctors discovered that the patients started looking younger and healthier after they have had about 20 treatments. It has applications in liver and kidney disease, protecting the stomach lining from NSAID damage and in Psoriasis patients.

  

 In 2006 Plaquex® Oral Gel Capsules were added to the treatment regimen. They improve blood lipids and liver and kidney function and thereby aid in the prevention of plaque deposits in between IV treatment sessions and after the infusion series is completed.

  

 Chosen for their uncompromising quality and superior performance, AnazaoHealth® looks forward to sharing more than two decades of experience with you. Their staff of pharmacists, technicians and account managers are available to answer your questions about preparations, ordering and delivery.

  

 

AnazaoHealth® is fully licensed to provide prescriptions in all 50 states. Plaquex is made in AnazaoHealth's 503 B Outsourcing Facility for office use. We encourage you to learn more about them by visiting their website at www.anazaohealth.com.

Pure Integrative Pharmacy in Vancouver, B.C., Canada has recently become the authorized Plaquex compounding pharmacy for Canada.Their website is www.purepharmacy.com

  

  

 This website will provide you with help to find basic information, detailed studies, important contact information and to answer frequently asked questions regarding the original Plaquex® product.

  

  

 References

 

1 Elevation of HDL, LDL, and liver enzymes in the beginning which normalize with continuing treatment

 Leuschner, F. A. Leuschner. Research report no. 0050/84 of December 27, 1983
 Maeda, A. et al. Gendai no Shinryo 22 (1980) 189-192 and 1461-1465
 Fasoli, A.  Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs
 G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262
 Suo, T. et al.   Kiso to Rinsho 15 (1981) 3046-3051
 Belousova, S.S. et al.  Kardiologiya 25 (1985) 112-115
 Izumi, H.  et al. 11th Proceed Jap. Atheroscl. Socl, Tokyo 1979
 Nakamura, H.  et al. Jap J. New. Rem. Clin. 22 (1973) 1565-1575
 Spigai, C. Med. Heute 19 (1970) 197-198
 Thurnherr A. Therapiewoche 7 (1956) 116
 Friehe, H., R. Fontaine Report no. 840160 of December 16, 1978
 Arsenio, L.  et al. Clin. Ter. 114 (1985) 117-127
 Tomasevic, M. Unpublished report no. 842746
 Takahashi, S.  Shinryo to Shinyaku 17 (1980) 3051-3064
 Blagosklonov, A.S.  et al. Kardiologiya 26 (1986) 35-38

2 Angina Pectoris

 Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95
 Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984
 Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9

  Peripheral Vascular

 Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243
 Luczac, Z., R. Leutschaft.  Unpublished report no. 842762
 Pristautz, H.  Munch. Med. Wschr. 117 (1975) 583-586
 Hevelke, G. et al.  Med. Welt 30 (1980) 593-602

  Liver disease

 Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int. Sympos. Atheroscl., Tokyo 1976 and:
 Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987

 Salvioli, G.  Scand J. Gastroenterology 12 (1977) 841-847
 Salvioli, G. et al. Gut 19 (1978) 844-850
 Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99

 Cell Membranes

 Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer Berlin  1976, 228-236
 Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38
3 Nei’mark Al, Zhukov, VN et al.  Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy
Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec
4 Kuntz, E.  The “essential” phospholipids in hepatology – 50 years of experimental and clinical experiences
               Z Gastroenterol (Suppl 2) 1991: 29:7-13